[
  {
    "ts": null,
    "headline": "Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD), in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers.",
    "url": "https://finnhub.io/api/news?id=01d7dd0c9e31b4f45980ec2bc74cee5a4efadf5143722d13f84f3b52588fb388",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758839940,
      "headline": "Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease",
      "id": 136888258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD), in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers.",
      "url": "https://finnhub.io/api/news?id=01d7dd0c9e31b4f45980ec2bc74cee5a4efadf5143722d13f84f3b52588fb388"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Trades Down, Here Is Why",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was intended to prevent muscle loss in patients taking its blockbuster obesity treatment, Zepbound.",
    "url": "https://finnhub.io/api/news?id=cca304d74cf4474372df6835ab1afe8c4728d12db1875b5a17d14a6365ea0425",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758833441,
      "headline": "Eli Lilly (LLY) Stock Trades Down, Here Is Why",
      "id": 136888259,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was intended to prevent muscle loss in patients taking its blockbuster obesity treatment, Zepbound.",
      "url": "https://finnhub.io/api/news?id=cca304d74cf4474372df6835ab1afe8c4728d12db1875b5a17d14a6365ea0425"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Presses Pause On Zepbound-Bimagrumab Diabetes Study",
    "summary": "Zepbound-bimagrumab study scrapped, other research still ongoing",
    "url": "https://finnhub.io/api/news?id=454dbcc8cf015ddb6e85f60e510cb3c264741a0ee638cb8a94e165df8ce1c284",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758829199,
      "headline": "Eli Lilly Presses Pause On Zepbound-Bimagrumab Diabetes Study",
      "id": 136888260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zepbound-bimagrumab study scrapped, other research still ongoing",
      "url": "https://finnhub.io/api/news?id=454dbcc8cf015ddb6e85f60e510cb3c264741a0ee638cb8a94e165df8ce1c284"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets European Authorization for Alzheimer's Treatment",
    "summary": "Eli Lilly Gets European Authorization for Alzheimer's Treatment",
    "url": "https://finnhub.io/api/news?id=bb75b656ebab6d6d805899bf9ff7667bd072b0798bf458655fa87eaab77e43ac",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758826800,
      "headline": "Eli Lilly Gets European Authorization for Alzheimer's Treatment",
      "id": 136921044,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Gets European Authorization for Alzheimer's Treatment",
      "url": "https://finnhub.io/api/news?id=bb75b656ebab6d6d805899bf9ff7667bd072b0798bf458655fa87eaab77e43ac"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). In the Phase 3 EMBER-3 trial, Inluriyo reduced the",
    "url": "https://finnhub.io/api/news?id=66a53e8d0fd4af1e311c572a4754f1fe50097a27785a4fe6b494252c76f9ee99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758823260,
      "headline": "U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer",
      "id": 136885576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). In the Phase 3 EMBER-3 trial, Inluriyo reduced the",
      "url": "https://finnhub.io/api/news?id=66a53e8d0fd4af1e311c572a4754f1fe50097a27785a4fe6b494252c76f9ee99"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Highlights Jacobs Solutions Role in Data Centers and Pharma Projects",
    "summary": "Jacobs Solutions Inc. (NYSE:J) is one of the relatively cheap S&P 500 stocks Jim Cramer talked about. During the episode, Cramer noted the company’s role in advanced projects and strong growth prospects. He stated: “Finally, there’s Jacobs Solutions. That’s the engineering construction firm. We just had them on last week. Jacobs is involved in all […]",
    "url": "https://finnhub.io/api/news?id=cc6964dfb78fd7e97f101dc0fd9a34f1ff5f345a4c20c0da788b05a799d92586",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758819943,
      "headline": "Jim Cramer Highlights Jacobs Solutions Role in Data Centers and Pharma Projects",
      "id": 136885577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Jacobs Solutions Inc. (NYSE:J) is one of the relatively cheap S&P 500 stocks Jim Cramer talked about. During the episode, Cramer noted the company’s role in advanced projects and strong growth prospects. He stated: “Finally, there’s Jacobs Solutions. That’s the engineering construction firm. We just had them on last week. Jacobs is involved in all […]",
      "url": "https://finnhub.io/api/news?id=cc6964dfb78fd7e97f101dc0fd9a34f1ff5f345a4c20c0da788b05a799d92586"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ebc8833628e8c8c74299158c601764bdc90146b8edd62e7bb5805e9fbb395b2d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758817860,
      "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "id": 136921046,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ebc8833628e8c8c74299158c601764bdc90146b8edd62e7bb5805e9fbb395b2d"
    }
  },
  {
    "ts": null,
    "headline": "FHLC: Fidelity's U.S. Health Care ETF Balances Quality, Safety, And Growth",
    "summary": "FHLC offers cap-weighted exposure to over 300 U.S. Health Care stocks for a low 0.084% expense ratio. Click here for more information on FHLC ETF.",
    "url": "https://finnhub.io/api/news?id=f55c75b66af18ba1ea5162548c360c976ed73e70d4b6b1d66edc25d5e375fd1a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758816109,
      "headline": "FHLC: Fidelity's U.S. Health Care ETF Balances Quality, Safety, And Growth",
      "id": 136886314,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/124683308/image_124683308.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "FHLC offers cap-weighted exposure to over 300 U.S. Health Care stocks for a low 0.084% expense ratio. Click here for more information on FHLC ETF.",
      "url": "https://finnhub.io/api/news?id=f55c75b66af18ba1ea5162548c360c976ed73e70d4b6b1d66edc25d5e375fd1a"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?",
    "summary": "AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.",
    "url": "https://finnhub.io/api/news?id=d31d6edd9854fc45e63b74d7037b162c23113955d0eef5fe36364406db0eaaf8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758815520,
      "headline": "AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?",
      "id": 136884808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.",
      "url": "https://finnhub.io/api/news?id=d31d6edd9854fc45e63b74d7037b162c23113955d0eef5fe36364406db0eaaf8"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein",
    "summary": "Investing.com -- Bernstein reiterated its Outperform rating on Novo Nordisk, saying the company’s diabetes and obesity GLP-1 portfolio remains well-positioned following fresh data from the European Association for the Study of Diabetes congress in September.",
    "url": "https://finnhub.io/api/news?id=bf33286c896ce90cf35941ec1a916cbad3a733955f962017f5147fe096b33470",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758815313,
      "headline": "Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein",
      "id": 136882927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Bernstein reiterated its Outperform rating on Novo Nordisk, saying the company’s diabetes and obesity GLP-1 portfolio remains well-positioned following fresh data from the European Association for the Study of Diabetes congress in September.",
      "url": "https://finnhub.io/api/news?id=bf33286c896ce90cf35941ec1a916cbad3a733955f962017f5147fe096b33470"
    }
  },
  {
    "ts": null,
    "headline": "Sometimes 'boring' is better: Defensive stocks for cooling AI rally",
    "summary": "US stocks (^DJI, ^IXIC, ^GSPC) trend lower at Thursday's session open as the market's AI-fueled rally begins to cool, just as major artificial intelligence players announce multibillion-dollar deals, including Nvidia's (NVDA) partnership with Intel (INTC), OpenAI, and Alibaba (BABA). Winthrop Capital Chief Investment Officer Adam Coons sits down with the Morning Brief's Julie Hyman to talk more about defensive investing plays. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=870f5a88fe3139d1f75a27263899b8f2949e3df20f20c795244c64b9f8f88f35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758810285,
      "headline": "Sometimes 'boring' is better: Defensive stocks for cooling AI rally",
      "id": 136882771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US stocks (^DJI, ^IXIC, ^GSPC) trend lower at Thursday's session open as the market's AI-fueled rally begins to cool, just as major artificial intelligence players announce multibillion-dollar deals, including Nvidia's (NVDA) partnership with Intel (INTC), OpenAI, and Alibaba (BABA). Winthrop Capital Chief Investment Officer Adam Coons sits down with the Morning Brief's Julie Hyman to talk more about defensive investing plays. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=870f5a88fe3139d1f75a27263899b8f2949e3df20f20c795244c64b9f8f88f35"
    }
  },
  {
    "ts": null,
    "headline": "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst",
    "summary": "Immuneering Corporation upgraded to Strong Buy after positive phase 2a data in pancreatic cancer. Click here to find out why IMRX stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=a9b61f5b9b7c05e5f8d9e6c0fcaaf26a7dc5d01cecfbffa23fe5f46949cad10f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758809987,
      "headline": "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst",
      "id": 136885293,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2234628683/image_2234628683.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Immuneering Corporation upgraded to Strong Buy after positive phase 2a data in pancreatic cancer. Click here to find out why IMRX stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=a9b61f5b9b7c05e5f8d9e6c0fcaaf26a7dc5d01cecfbffa23fe5f46949cad10f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets FDA Approval for Breast Cancer Drug Inluriyo",
    "summary": "Eli Lilly Gets FDA Approval for Breast Cancer Drug Inluriyo",
    "url": "https://finnhub.io/api/news?id=08f01e2b13aed12ec0c5edd79c0476253009f4ac72cdc4691bad3667b640b560",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758809820,
      "headline": "Eli Lilly Gets FDA Approval for Breast Cancer Drug Inluriyo",
      "id": 136921047,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Gets FDA Approval for Breast Cancer Drug Inluriyo",
      "url": "https://finnhub.io/api/news?id=08f01e2b13aed12ec0c5edd79c0476253009f4ac72cdc4691bad3667b640b560"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Dragged Eli Lilly and Company (LLY) Down in Q2",
    "summary": "PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P […]",
    "url": "https://finnhub.io/api/news?id=9c39381fd9573baa810951a38b2b3b5ba18cbc16dbc9c6e66069a8259661a224",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758808958,
      "headline": "Here’s What Dragged Eli Lilly and Company (LLY) Down in Q2",
      "id": 136882929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P […]",
      "url": "https://finnhub.io/api/news?id=9c39381fd9573baa810951a38b2b3b5ba18cbc16dbc9c6e66069a8259661a224"
    }
  },
  {
    "ts": null,
    "headline": "Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce",
    "summary": "While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.",
    "url": "https://finnhub.io/api/news?id=9e302f6e6ad9e589fa1ad7a2ed8a09bd22a59011910931e0e5f5fa5dfc139ede",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758806101,
      "headline": "Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce",
      "id": 136883950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.",
      "url": "https://finnhub.io/api/news?id=9e302f6e6ad9e589fa1ad7a2ed8a09bd22a59011910931e0e5f5fa5dfc139ede"
    }
  },
  {
    "ts": null,
    "headline": "Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?",
    "summary": "VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.",
    "url": "https://finnhub.io/api/news?id=38def090a0c127104af513227d5e068d4161df78f693d6c227bb45b865a9f39b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758806100,
      "headline": "Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?",
      "id": 136882930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.",
      "url": "https://finnhub.io/api/news?id=38def090a0c127104af513227d5e068d4161df78f693d6c227bb45b865a9f39b"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: U.S. stocks dip; Dollar Index rises after strong economic data reports",
    "summary": "U.S. stocks look to snap two-day losing streak as quarter winds to a close",
    "url": "https://finnhub.io/api/news?id=eb8d7658906fd6ac48558939abf3508f9d9e5691b429620e37f78bbd5a9f64c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758803280,
      "headline": "Stock Market Today: U.S. stocks dip; Dollar Index rises after strong economic data reports",
      "id": 136883617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. stocks look to snap two-day losing streak as quarter winds to a close",
      "url": "https://finnhub.io/api/news?id=eb8d7658906fd6ac48558939abf3508f9d9e5691b429620e37f78bbd5a9f64c1"
    }
  },
  {
    "ts": null,
    "headline": "Denmark's 'Novo Town' holds its breath as Wegovy fever fades",
    "summary": "STORY: Denmark’s Kalundborg, known as \"Novo Town\", is used to ever-expanding facilities to meet demand for Novo Nordisk's Wegovy weight-loss drug.What’s less familiar is the worry that this titan drugmaker plans to cut 5,000 jobs in its home market.  Tina Beck-Nilsson is the town’s deputy mayor. “I think everyone just took our breath in when we heard how many people they have to lay off because how is it going to affect us here in Kalundborg?\"   Novo Nordisk’s launch of Wegovy in 2021 made it Europe’s most valuable company. Since then, fierce competition from U.S. rival Eli Lilly, and a growing number of copycats have slowed Wegovy sales.And Novo Nordisk's share price has plunged by more than $400 billion.The pharmaceutical remains central to the Danish economy that still outpaces much of the euro zone…But the end of its rapid growth has weighed. At its peak, Novo's market value exceeded Denmark's entire economic output.The central bank on Wednesday (September 24) cut its growth forecasts for 2025-2027, citing U.S. tariffs and weaker pharmaceutical sector growth. Kalundborg is the core of Novo Nordisk's production empire - and local house prices have spiked in a market which has now slowed. But its mayor Martin Damm thinks that the impact will be short-term.\"Right now they are expanding, building new factories for 65 billion Danish crowns. When they are finished, I don't think they will have them empty. I think they will have people inside to produce, so they can sell what they are doing in the world.”Novo Nordisk employs around 5,500 people in this town of 16,500.",
    "url": "https://finnhub.io/api/news?id=f2aefe88a02fe4255be6b8420f12f8cb3f6e60b9551c4682036c63e31a2c208b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758802861,
      "headline": "Denmark's 'Novo Town' holds its breath as Wegovy fever fades",
      "id": 136882931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Denmark’s Kalundborg, known as \"Novo Town\", is used to ever-expanding facilities to meet demand for Novo Nordisk's Wegovy weight-loss drug.What’s less familiar is the worry that this titan drugmaker plans to cut 5,000 jobs in its home market.  Tina Beck-Nilsson is the town’s deputy mayor. “I think everyone just took our breath in when we heard how many people they have to lay off because how is it going to affect us here in Kalundborg?\"   Novo Nordisk’s launch of Wegovy in 2021 made it Europe’s most valuable company. Since then, fierce competition from U.S. rival Eli Lilly, and a growing number of copycats have slowed Wegovy sales.And Novo Nordisk's share price has plunged by more than $400 billion.The pharmaceutical remains central to the Danish economy that still outpaces much of the euro zone…But the end of its rapid growth has weighed. At its peak, Novo's market value exceeded Denmark's entire economic output.The central bank on Wednesday (September 24) cut its growth forecasts for 2025-2027, citing U.S. tariffs and weaker pharmaceutical sector growth. Kalundborg is the core of Novo Nordisk's production empire - and local house prices have spiked in a market which has now slowed. But its mayor Martin Damm thinks that the impact will be short-term.\"Right now they are expanding, building new factories for 65 billion Danish crowns. When they are finished, I don't think they will have them empty. I think they will have people inside to produce, so they can sell what they are doing in the world.”Novo Nordisk employs around 5,500 people in this town of 16,500.",
      "url": "https://finnhub.io/api/news?id=f2aefe88a02fe4255be6b8420f12f8cb3f6e60b9551c4682036c63e31a2c208b"
    }
  },
  {
    "ts": null,
    "headline": "Lilly stops trial of muscle-sparing obesity drug",
    "summary": "Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines.",
    "url": "https://finnhub.io/api/news?id=8fd71bdbab3739aacd9f68d8110e89391142363262272df235fabf1c8c8b620e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758801333,
      "headline": "Lilly stops trial of muscle-sparing obesity drug",
      "id": 136884261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines.",
      "url": "https://finnhub.io/api/news?id=8fd71bdbab3739aacd9f68d8110e89391142363262272df235fabf1c8c8b620e"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today",
    "summary": "The latest data from the company's oral weight loss drug is bullish for the stock.",
    "url": "https://finnhub.io/api/news?id=087d02b764f636cfe6abfcc21dc689abcb9dd4652ab432408e5f1713de389944",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758800700,
      "headline": "1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today",
      "id": 136882932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The latest data from the company's oral weight loss drug is bullish for the stock.",
      "url": "https://finnhub.io/api/news?id=087d02b764f636cfe6abfcc21dc689abcb9dd4652ab432408e5f1713de389944"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript",
    "summary": "Eli Lilly and Company (NYSE:LLY) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDTCompany ParticipantsLucas Montarce -...",
    "url": "https://finnhub.io/api/news?id=248c40af37676d09f7fe277659c4dce4cef3621682954694bbee1140595620c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758799666,
      "headline": "Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript",
      "id": 136882665,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (NYSE:LLY) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDTCompany ParticipantsLucas Montarce -...",
      "url": "https://finnhub.io/api/news?id=248c40af37676d09f7fe277659c4dce4cef3621682954694bbee1140595620c0"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Eli Lilly Plans to Launch Investigational Weight Loss Drug Orforglipron in India",
    "summary": "Eli Lilly (LLY) plans to introduce its experimental weight loss pill orforglipron in India, Reuters",
    "url": "https://finnhub.io/api/news?id=fd6943b574d23e9e3e21bf7fcb8fd9d78193c9ccbdcaf8c306656cae8d0b43f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758799472,
      "headline": "Market Chatter: Eli Lilly Plans to Launch Investigational Weight Loss Drug Orforglipron in India",
      "id": 136882933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) plans to introduce its experimental weight loss pill orforglipron in India, Reuters",
      "url": "https://finnhub.io/api/news?id=fd6943b574d23e9e3e21bf7fcb8fd9d78193c9ccbdcaf8c306656cae8d0b43f4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Buying The Dip With Confidence",
    "summary": "Discover why Eli Lilly is a strong buy, led by innovative diabetes drugs and AI-driven research.",
    "url": "https://finnhub.io/api/news?id=d1384f3f931f5cbf057b501c14eee477eedf5d743c1761be674e1e8a21cf8dfb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758797614,
      "headline": "Eli Lilly: Buying The Dip With Confidence",
      "id": 136882521,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355656320/image_1355656320.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Eli Lilly is a strong buy, led by innovative diabetes drugs and AI-driven research.",
      "url": "https://finnhub.io/api/news?id=d1384f3f931f5cbf057b501c14eee477eedf5d743c1761be674e1e8a21cf8dfb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.",
    "summary": "Investors once speculated that Pfizer might consider acquiring Viking.",
    "url": "https://finnhub.io/api/news?id=8187fb09c720eb0007c590e51e1b37224fdee0f1d3710cfcb8f8717e859fd2e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758787920,
      "headline": "Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.",
      "id": 136882934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors once speculated that Pfizer might consider acquiring Viking.",
      "url": "https://finnhub.io/api/news?id=8187fb09c720eb0007c590e51e1b37224fdee0f1d3710cfcb8f8717e859fd2e2"
    }
  },
  {
    "ts": null,
    "headline": "Can a multibillion-dollar deal put Pfizer in the obesity big leagues?",
    "summary": "After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.",
    "url": "https://finnhub.io/api/news?id=78b04e842307cb30b0d4566de77ac5e4d752edf54bae418ae5c664d9c31b2193",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758787200,
      "headline": "Can a multibillion-dollar deal put Pfizer in the obesity big leagues?",
      "id": 136882935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.",
      "url": "https://finnhub.io/api/news?id=78b04e842307cb30b0d4566de77ac5e4d752edf54bae418ae5c664d9c31b2193"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly plans to bring experimental weight-loss pill in India",
    "summary": "MUMBAI (Reuters) -Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on Thursday, offering an alternative to injectables that many patients in the world's most populous nation resist.  Orforglipron is part of a new class of GLP-1 drugs that suppress appetite and follow the same pathway targeted by Eli Lilly's blockbuster tirzepatide, sold globally as the blockbuster Mounjaro for diabetes and Zepbound for weight loss.  The drug has not been launched anywhere globally but Lilly plans to file for approval of orforglipron with regulators in the United States, Britain, European Union, Japan and China.",
    "url": "https://finnhub.io/api/news?id=b1c1d532bdfa4de846d9d2efc3eb3f5ec697428205bbea6f3e2df88a2741a3ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758777146,
      "headline": "Eli Lilly plans to bring experimental weight-loss pill in India",
      "id": 136882936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MUMBAI (Reuters) -Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on Thursday, offering an alternative to injectables that many patients in the world's most populous nation resist.  Orforglipron is part of a new class of GLP-1 drugs that suppress appetite and follow the same pathway targeted by Eli Lilly's blockbuster tirzepatide, sold globally as the blockbuster Mounjaro for diabetes and Zepbound for weight loss.  The drug has not been launched anywhere globally but Lilly plans to file for approval of orforglipron with regulators in the United States, Britain, European Union, Japan and China.",
      "url": "https://finnhub.io/api/news?id=b1c1d532bdfa4de846d9d2efc3eb3f5ec697428205bbea6f3e2df88a2741a3ce"
    }
  }
]